643 related articles for article (PubMed ID: 14615704)
21. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
22. Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial.
Perry EB; Berman RM; Sanacora G; Anand A; Lynch-Colonese K; Charney DS
J Clin Psychiatry; 2004 Feb; 65(2):238-43. PubMed ID: 15003079
[TBL] [Abstract][Full Text] [Related]
23. Pindolol augmentation of antidepressant response.
Artigas F; Adell A; Celada P
Curr Drug Targets; 2006 Feb; 7(2):139-47. PubMed ID: 16475955
[TBL] [Abstract][Full Text] [Related]
24. Blockade of 5-HT1A receptors by (+/-)-pindolol potentiates cortical 5-HT outflow, but not antidepressant-like activity of paroxetine: microdialysis and behavioral approaches in 5-HT1A receptor knockout mice.
Guilloux JP; David DJ; Guiard BP; Chenu F; Repérant C; Toth M; Bourin M; Gardier AM
Neuropsychopharmacology; 2006 Oct; 31(10):2162-72. PubMed ID: 16452992
[TBL] [Abstract][Full Text] [Related]
25. Effects of combined administration of 5-HT1A and/or 5-HT1B receptor antagonists and paroxetine or fluoxetine in the forced swimming test in rats.
Tatarczyńska E; Kłodzińska A; Chojnacka-Wójcik E
Pol J Pharmacol; 2002; 54(6):615-23. PubMed ID: 12866716
[TBL] [Abstract][Full Text] [Related]
26. Effects on sleep architecture of pindolol, paroxetine and their combination in healthy volunteers.
Bell C; Wilson S; Rich A; Bailey J; Nutt D
Psychopharmacology (Berl); 2003 Mar; 166(2):102-10. PubMed ID: 12536263
[TBL] [Abstract][Full Text] [Related]
27. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. Réseau de Recherche et d'Expérimentation Psychopharmacologique.
Bordet R; Thomas P; Dupuis B
Am J Psychiatry; 1998 Oct; 155(10):1346-51. PubMed ID: 9766765
[TBL] [Abstract][Full Text] [Related]
28. Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression.
Portella MJ; de Diego-Adeliño J; Ballesteros J; Puigdemont D; Oller S; Santos B; Álvarez E; Artigas F; Pérez V
J Clin Psychiatry; 2011 Jul; 72(7):962-9. PubMed ID: 21034693
[TBL] [Abstract][Full Text] [Related]
29. 5-HT(1A) agonist potential of pindolol: electrophysiologic studies in the dorsal raphe nucleus and hippocampus.
Sprouse J; Braselton J; Reynolds L
Biol Psychiatry; 2000 Jun; 47(12):1050-5. PubMed ID: 10862804
[TBL] [Abstract][Full Text] [Related]
30. Positron emission tomography study of pindolol occupancy of 5-HT(1A) receptors in humans: preliminary analyses.
Martinez D; Mawlawi O; Hwang DR; Kent J; Simpson N; Parsey RV; Hashimoto T; Slifstein M; Huang Y; Van Heertum R; Abi-Dargham A; Caltabiano S; Malizia A; Cowley H; Mann JJ; Laruelle M
Nucl Med Biol; 2000 Jul; 27(5):523-7. PubMed ID: 10962261
[TBL] [Abstract][Full Text] [Related]
31. Pindolol augmentation of antidepressant therapy.
McAskill R; Mir S; Taylor D
Br J Psychiatry; 1998 Sep; 173():203-8. PubMed ID: 9926094
[TBL] [Abstract][Full Text] [Related]
32. Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial.
Dannon PN; Sasson Y; Hirschmann S; Iancu I; Grunhaus LJ; Zohar J
Eur Neuropsychopharmacol; 2000 May; 10(3):165-9. PubMed ID: 10793318
[TBL] [Abstract][Full Text] [Related]
33. Pindolol augmentation of selective serotonin reuptake inhibitors: accounting for the variability of results of placebo-controlled double-blind studies in patients with major depression.
Segrave R; Nathan PJ
Hum Psychopharmacol; 2005 Apr; 20(3):163-74. PubMed ID: 15648095
[TBL] [Abstract][Full Text] [Related]
34. Cost effectiveness study of a year follow-up of selective serotonin reuptake inhibitor (SSRI) and augmentor combination compared with SSRI and placebo.
Tome MB; Isaac MT
Int Clin Psychopharmacol; 1998 Jul; 13(4):175-82. PubMed ID: 9727728
[TBL] [Abstract][Full Text] [Related]
35. A mathematical model for paroxetine antidepressant effect time course and its interaction with pindolol.
Gruwez B; Dauphin A; Tod M
J Pharmacokinet Pharmacodyn; 2005 Dec; 32(5-6):663-83. PubMed ID: 16307210
[TBL] [Abstract][Full Text] [Related]
36. Acute effects of combining citalopram and pindolol on regional brain serotonin synthesis in sham operated and olfactory bulbectomized rats.
Nguyen KQ; Tohyama Y; Watanabe A; Hasegawa S; Skelin I; Diksic M
Neurochem Int; 2009; 54(3-4):161-71. PubMed ID: 19073228
[TBL] [Abstract][Full Text] [Related]
37. An index of 5-HT synthesis changes during early antidepressant treatment: alpha-[11C]methyl-L-tryptophan PET study.
Berney A; Nishikawa M; Benkelfat C; Debonnel G; Gobbi G; Diksic M
Neurochem Int; 2008; 52(4-5):701-8. PubMed ID: 17928105
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression.
Maes M; Vandoolaeghe E; Desnyder R
J Affect Disord; 1996 Dec; 41(3):201-10. PubMed ID: 8988452
[TBL] [Abstract][Full Text] [Related]
39. Pharmacologic approaches to treatment resistant depression: Evidences and personal experience.
Tundo A; de Filippis R; Proietti L
World J Psychiatry; 2015 Sep; 5(3):330-41. PubMed ID: 26425446
[TBL] [Abstract][Full Text] [Related]
40. Preclinical and clinical characterization of the selective 5-HT(1A) receptor antagonist DU-125530 for antidepressant treatment.
Scorza MC; Lladó-Pelfort L; Oller S; Cortés R; Puigdemont D; Portella MJ; Pérez-Egea R; Alvarez E; Celada P; Pérez V; Artigas F
Br J Pharmacol; 2012 Nov; 167(5):1021-34. PubMed ID: 22050051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
